Role of Biomarkers in Disease Progression in Samples From Patients With Acute Myeloid Leukemia
NCT ID: NCT01500499
Last Updated: 2016-05-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
20 participants
OBSERVATIONAL
2011-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
PURPOSE: This research trial studies the role of biomarkers in disease progression in samples from patients with acute myeloid leukemia.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Gene Expression in Samples From Patients With T-Cell Acute Lymphoblastic Leukemia
NCT01520246
Biomarker Changes in Samples From Young Patients With Acute Myeloid Leukemia
NCT01139931
Studying Genes in Samples From Younger Patients With Acute Lymphoblastic Leukemia
NCT01653613
Blood and Tumor Tissue Samples From Young Patients With Acute Myeloid Leukemia
NCT01139333
Biomarkers in DNA Samples From Patients With High-Risk Acute Lymphoblastic Leukemia
NCT01119586
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
* To determine the subcellular localization of the MLL-AF1q fusion protein in leukemia cells.
OUTLINE: Cryopreserved specimens are analyzed for MLL-AF1q fusion protein and AF1 gene expression by mass spectrometry, western blot analysis, semi-quantitative PCR, and qPCR.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
gene expression analysis
gene rearrangement analysis
polymerase chain reaction
protein analysis
western blotting
laboratory biomarker analysis
mass spectrometry
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Cryopreserved acute myeloid leukemia specimens
PATIENT CHARACTERISTICS:
* Not specified
PRIOR CONCURRENT THERAPY:
* Not specified
30 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Cancer Institute (NCI)
NIH
Children's Oncology Group
NETWORK
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Julie D. Saba, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
UCSF Benioff Children's Hospital Oakland
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
COG-AAML12B2
Identifier Type: OTHER
Identifier Source: secondary_id
AAML12B2
Identifier Type: OTHER
Identifier Source: secondary_id
NCI-2012-00099
Identifier Type: OTHER
Identifier Source: secondary_id
AAML12B2
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.